Ovid’s Bright Spark: A Most Promising Turn

by

Now, one wouldn’t normally get terribly excited about the doings of biopharmaceutical companies, what with all the complicated science and the ever-present possibility of things going horribly awry. However, Ovid Therapeutics (OVID +13.18%) has, as it were, thrown a rather spiffing cat amongst the pigeons this morning, and a rise of over 18% is enough to make even the most hardened City gent sit up and take notice. They’re a firm devoted to tackling epilepsy and other brainy troubles, and today’s cheerful news revolves around their most promising prospect, a concoction called OV329.

A Next-Generation Remedy

The company describes OV329 as a “next-generation GABA-aminotransferase (GABA-AT) inhibitor,” which sounds frightfully technical, doesn’t it? Essentially, it’s a bit of kit designed to soothe over-excited brains, and it does this by boosting levels of something called GABA. Think of it as a calming influence, a sort of mental chamomile tea, if you will. The idea is to dial down the brain’s fizz, and thus, reduce those pesky seizures.

The key thing for the discerning investor to grasp is the “next-generation” bit. You see, there was an earlier version of this sort of thing, Vigabatrin (Sabril), but it had a rather unfortunate side effect – a tendency to cause permanent vision loss. A dashedly inconvenient outcome, one might observe. Ovid, with a touch of brilliance, appears to have crafted a version that’s not only more potent but also, crucially, less likely to result in one stumbling about in the dark.

The Latest Intelligence

The good news arrived today in the form of data from a Phase 1 study, which, as these things go, is a bit like a preliminary canter before the Grand National. They tested a 7 mg dose of OV329 (having already tried 3mg and 5mg), and the report came back with a most agreeable finding: “no treatment-related adverse events.” In plainer English, nobody reported feeling any the worse for wear. Even better, ophthalmic assessments revealed “no evidence of ophthalmic or retinal changes.” A truly splendid result, wouldn’t you agree?

Loading widget...

What Next for Ovid?

This safety and tolerability data is most encouraging, and management has announced a $60 million private placement – a rather substantial sum, if one may say so. They intend to use this windfall to explore OV329’s potential in other areas, such as tuberous sclerosis complex seizures and infantile spasms, as well as continuing a Phase 2 trial for those particularly stubborn focal onset seizures.

These are exciting steps forward, of course, but as anyone with even a passing acquaintance with pharmaceutical companies and clinical trials will tell you, there’s always a certain amount of risk involved. However, with a bit of luck, and a dash of scientific ingenuity, Ovid Therapeutics might just have stumbled upon something rather special. A most promising turn of events, indeed.

Read More

2026-03-18 21:22